PLX [AMEX]
Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own17.59% Shs Outstand50.67M Perf Week-5.99%
Market Cap79.54M Forward P/E- EPS next Y- Insider Trans1.25% Shs Float41.64M Perf Month30.83%
Income- PEG- EPS next Q-0.15 Inst Own9.70% Short Float / Ratio4.95% / 4.35 Perf Quarter53.92%
Sales47.57M P/S1.67 EPS this Y37.10% Inst Trans- Short Interest2.06M Perf Half Y46.73%
Book/sh-0.23 P/B- EPS next Y- ROA- Target Price- Perf Year90.97%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range0.70 - 2.00 Perf YTD14.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-21.50% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low124.29% ATR0.11
Employees202 Current Ratio- Sales Q/Q17.70% Oper. Margin- RSI (14)57.27 Volatility12.81% 6.92%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.34 Prev Close1.52
ShortableYes LT Debt/Eq- EarningsNov 14 BMO Payout- Avg Volume474.00K Price1.57
Recom2.00 SMA204.11% SMA5021.73% SMA20036.39% Volume636,744 Change3.29%
Jun-08-20Reiterated H.C. Wainwright Buy $3 → $11
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Show Previous Ratings
Jan-06-23 07:04AM
Jan-03-23 06:50AM
Dec-21-22 04:30PM
Dec-05-22 06:50AM
Dec-04-22 09:00AM
02:59PM Loading…
Nov-30-22 02:59PM
Nov-15-22 04:46AM
Nov-14-22 06:50AM
06:30AM
Nov-07-22 06:50AM
Sep-21-22 08:00AM
Sep-12-22 12:40PM
Sep-06-22 06:50AM
Aug-16-22 05:55AM
Aug-15-22 06:50AM
06:50AM Loading…
Aug-08-22 06:50AM
Jun-30-22 04:30PM
Jun-14-22 09:23AM
May-26-22 04:30PM
May-17-22 06:13AM
May-16-22 06:50AM
May-09-22 06:50AM
Apr-07-22 10:05AM
Apr-05-22 07:40AM
Apr-04-22 06:50AM
Apr-01-22 06:22AM
Mar-31-22 06:50AM
Mar-24-22 06:50AM
Mar-18-22 09:54AM
06:50AM
07:00AM Loading…
Mar-07-22 07:00AM
Feb-28-22 04:45AM
Feb-24-22 07:27AM
Feb-03-22 06:50AM
Dec-22-21 06:50AM
Nov-15-21 10:18AM
06:50AM
Nov-08-21 06:50AM
Oct-15-21 08:37AM
08:00AM
Oct-11-21 06:50AM
Aug-26-21 06:50AM
Aug-18-21 06:06AM
Aug-16-21 06:50AM
Aug-13-21 06:50AM
Aug-09-21 07:15AM
Aug-02-21 06:50AM
Jun-30-21 09:56AM
Jun-28-21 06:50AM
Jun-07-21 10:18PM
Jun-05-21 08:16PM
Jun-03-21 09:28AM
09:28AM
12:30AM
Jun-02-21 12:10PM
06:50AM
May-25-21 06:50AM
May-14-21 06:50AM
06:45AM
May-07-21 10:30AM
Apr-29-21 05:45AM
Apr-28-21 03:25PM
01:44PM
01:27PM
06:21AM
01:50AM
Apr-07-21 05:15AM
Mar-30-21 06:50AM
06:30AM
Mar-22-21 06:50AM
Mar-04-21 06:50AM
Feb-24-21 08:03AM
Feb-23-21 08:04AM
07:25AM
06:50AM
Feb-22-21 03:20AM
Feb-18-21 08:02AM
Feb-12-21 05:54AM
Feb-11-21 09:16PM
04:35PM
07:47AM
07:26AM
06:50AM
Feb-10-21 07:01AM
Feb-01-21 06:50AM
Jan-04-21 06:50AM
04:25AM
Dec-30-20 06:50AM
06:00AM
Dec-21-20 06:40AM
Dec-15-20 07:15AM
Nov-30-20 03:38PM
Nov-27-20 06:50AM
Nov-05-20 06:50AM
Oct-29-20 01:33PM
06:50AM
06:30AM
Oct-26-20 06:50AM
Oct-22-20 06:50AM
Oct-20-20 12:13PM
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundacao Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schwartz AharonDirectorJan 03Buy1.42110,000155,815174,000Jan 05 05:08 PM
Bashan DrorPresident and CEOApr 11Buy1.5068,000102,00068,000Apr 13 04:05 PM